Reference drug programs: Effectiveness and policy implications-Reference-Cited by-同舟云学术

Reference drug programs: Effectiveness and policy implications

Published:2007-04 Issue:1 Volume:81 Page:17-28
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Schneeweiss Sebastian

Publisher

Elsevier BV

Subject

Health Policy

Reference62 articles.

1. The Medicare prescription drug benefit: how will the game be played?;Huskamp;Health Affairs,2000

2. Pharmaceutical reference pricing in Germany: definition of therapeutic groups price setting through regression procedure and effects;Stargardt;Gesundheitswesen,2005

3. Predicting drug plan expenditure while planning reimbursement changes using policy simulation;Dormuth;Pharmacoeconomics,2005

4. Drug input and disposition,1999

5. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). The Journal of the American Medical Association 2002; 288:2981–2997.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A game theory data science-based mechanism for licensed pharmaceutical products concerning their deterioration: a case of a micro, small, and medium enterprise in Iran;Annals of Operations Research;2023-05-23

2. A new pricing mechanism for pharmaceutical supply chains: a game theory analytical approach for healthcare service;International Journal of Logistics Research and Applications;2022-09-15

3. Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries;Applied Health Economics and Health Policy;2019-09-11

4. Review of studies reporting actual prices for medicines;Expert Review of Pharmacoeconomics & Outcomes Research;2018-12-07

5. Therapeutic equivalence program: continued economic benefits in the context of rising costs and increased demand;Australian Health Review;2018